[{"address1": "9350 Kirby Drive", "address2": "Suite 300", "city": "Houston", "state": "TX", "zip": "77054", "country": "United States", "phone": "713 400 6400", "website": "https://markertherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Juan F. Vera M.D.", "age": 43, "title": "Co-Founder, CEO, President, Treasurer, Secretary & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 399251, "exercisedValue": 0, "unexercisedValue": 39127}, {"maxAge": 1, "name": "Ms. Elizabeth  Donnelly", "title": "Director of Administration", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Maria-Bernadette  Madel", "age": 33, "title": "Director of Corporate Operations & External Communications", "yearBorn": 1991, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Cheung", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Monic  Stuart M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Patricia  Allison", "title": "Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary  Newman Ph.D.", "age": 65, "title": "Head of Regulatory Affairs", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Z. Florkiewicz Sr., Ph.D.", "title": "Senior Director of Molecular Biology & Virology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.7, "open": 1.74, "dayLow": 1.66, "dayHigh": 1.79, "regularMarketPreviousClose": 1.7, "regularMarketOpen": 1.74, "regularMarketDayLow": 1.66, "regularMarketDayHigh": 1.79, "beta": 1.439, "forwardPE": -0.7853881, "volume": 61744, "regularMarketVolume": 61744, "averageVolume": 78933, "averageVolume10days": 105710, "averageDailyVolume10Day": 105710, "bid": 1.24, "ask": 2.16, "bidSize": 200, "askSize": 200, "marketCap": 18419480, "fiftyTwoWeekLow": 1.48, "fiftyTwoWeekHigh": 5.99, "priceToSalesTrailing12Months": 3.4136388, "fiftyDayAverage": 2.8884, "twoHundredDayAverage": 3.6194, "currency": "USD", "enterpriseValue": 6348739, "profitMargins": -1.7970799, "floatShares": 6661921, "sharesOutstanding": 10709000, "sharesShort": 232134, "sharesShortPriorMonth": 110755, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0217, "heldPercentInsiders": 0.098529994, "heldPercentInstitutions": 0.41787, "shortRatio": 3.13, "shortPercentOfFloat": 0.0301, "impliedSharesOutstanding": 10709000, "bookValue": 0.835, "priceToBook": 2.0598803, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -9633818, "trailingEps": -1.07, "forwardEps": -1.46, "lastSplitFactor": "1:10", "lastSplitDate": 1674777600, "enterpriseToRevenue": 1.177, "52WeekChange": -0.589372, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MRKR", "underlyingSymbol": "MRKR", "shortName": "Marker Therapeutics, Inc.", "longName": "Marker Therapeutics, Inc.", "firstTradeDateEpochUtc": 1026826200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f52316f7-d523-378a-bebe-a89c89d1c289", "messageBoardId": "finmb_1725474", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.72, "targetHighPrice": 19.0, "targetLowPrice": 4.0, "targetMeanPrice": 11.5, "targetMedianPrice": 11.5, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 8999664, "totalCashPerShare": 1.009, "quickRatio": 2.816, "currentRatio": 3.153, "totalRevenue": 5395849, "revenuePerShare": 0.606, "returnOnAssets": -0.41923, "returnOnEquity": -0.79761004, "grossProfits": -5603129, "freeCashflow": -5249834, "operatingCashflow": -8574773, "revenueGrowth": 6.477, "grossMargins": -1.0384101, "operatingMargins": -1.24603, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]